Glaucoma Research and Clinical Advances
Glaucoma Research and Clinical Advances 2018 to 2020
Volume 2 of the Glaucoma Research and Clinical Advances series continues our desire to address glaucoma with a combination of science and speculation. As science expands, the emphasis is on data, interpretation, and dogma. We disagree; open minds open new approaches. Using methodologies that are primarily molecular and genetic, we seek to refine the causes of glaucoma as well as how it is best treated, especially incorporating thoughts and hypotheses about new methods of treatment. Glaucoma is a complex disease, and genetics proves that a variety of proteins are culpable at one level. At another level, however, there are likely final common pathways and numerous feedback loops which have defied explanations to date.
The search for answers goes on in basic science researcher’s laboratories and clinical ophthalmologist’s offices and operating rooms. We are all well-served by understanding that glaucoma is a neurodegenerative disease. Current attempts to solve the disease have focused on two strategic arenas:
- the trabecular meshwork function and its impact on intraocular pressure as a major risk factor for the disease; and
- the optic nerve dysfunction leading to visual loss.
Genetic mutations have yielded puzzling clues to the cause, but without resolution. For example, mutations in myocilin and optineurin genes are closely connected to the phenotype, but how do they cause the disease? In the next two years, priority areas of research are signaling pathway discoveries, biomarker panels, epigenetic factors, and continued genomic studies to yield answers to the common final pathways of the disease.
The final pathways are complex and redundant, such that the overlap of bio-informatics will be challenging. Current promising leads suggest the innate immune system holds important clues to both trabecular meshwork and optic nerve pathophysiology. When the primary open-angle glaucoma disease pathways are unraveled, drug discoveries and new treatment modalities will be available for better regulation of intraocular pressure and neuroprotection for the optic nerve. This volume discusses the glaucoma pipeline from several perspectives as well as future candidate classes. As always, the authors herein are urged to speculate on how the cure of glaucomatous optic nerve damage will yield to new treatments.
Glaucoma Research and Clinical Advances 2016 to 2018
This first volume of the Glaucoma Research and Clinical Advances series was conceived as a recurring project. It is neither book nor journal. Books are infrequently edited and rarely up-to-date for more than a year or two; journals are really devoted to the standard experimental format and no longer permit authors to wander into speculation or lengthy discussions of what might come next. There is room for a plurality of publishing approaches. All of these formats have their place and all have different purposes in moving a field forward.
Our volume is designed allow us to consolidate new information and hold forth on speculation in glaucoma. It does so in both the basic sciences and clinical sciences. It is our hope that this consolidation of hypotheses and theories, along with identifying new information and new speculation will propel us toward a more rapid cure for glaucoma. It will be refined and updated over the years to come to keep it the most essential of all references.